CA2910112C - Solid pharmaceutical composition - Google Patents

Solid pharmaceutical composition Download PDF

Info

Publication number
CA2910112C
CA2910112C CA2910112A CA2910112A CA2910112C CA 2910112 C CA2910112 C CA 2910112C CA 2910112 A CA2910112 A CA 2910112A CA 2910112 A CA2910112 A CA 2910112A CA 2910112 C CA2910112 C CA 2910112C
Authority
CA
Canada
Prior art keywords
acid
pharmaceutical composition
solid pharmaceutical
acidic substance
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2910112A
Other languages
English (en)
French (fr)
Other versions
CA2910112A1 (en
Inventor
Hiroshi Uchida
Masataka HANADA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of CA2910112A1 publication Critical patent/CA2910112A1/en
Application granted granted Critical
Publication of CA2910112C publication Critical patent/CA2910112C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/20—Mixing gases with liquids
    • B01F23/23—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids
    • B01F23/235—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids for making foam

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2910112A 2013-04-25 2014-04-24 Solid pharmaceutical composition Expired - Fee Related CA2910112C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013092171 2013-04-25
JP2013-092171 2013-04-25
PCT/JP2014/002308 WO2014174846A1 (ja) 2013-04-25 2014-04-24 固形医薬組成物

Publications (2)

Publication Number Publication Date
CA2910112A1 CA2910112A1 (en) 2014-10-30
CA2910112C true CA2910112C (en) 2021-02-16

Family

ID=51791434

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2910112A Expired - Fee Related CA2910112C (en) 2013-04-25 2014-04-24 Solid pharmaceutical composition

Country Status (7)

Country Link
US (1) US9603804B2 (enExample)
EP (1) EP2990038B1 (enExample)
JP (2) JP5651812B1 (enExample)
CN (1) CN105338982B (enExample)
CA (1) CA2910112C (enExample)
ES (1) ES2768651T3 (enExample)
WO (1) WO2014174846A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014174847A1 (ja) * 2013-04-25 2014-10-30 杏林製薬株式会社 固形医薬組成物
US10154993B2 (en) * 2014-10-23 2018-12-18 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
US20170246160A1 (en) * 2014-10-23 2017-08-31 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
JP6031217B1 (ja) * 2015-06-02 2016-11-24 杏林製薬株式会社 水性液剤
US10206917B2 (en) 2015-06-02 2019-02-19 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
JP6031216B1 (ja) * 2015-06-02 2016-11-24 杏林製薬株式会社 水性液剤
US10617684B2 (en) 2015-06-02 2020-04-14 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
WO2016195021A1 (ja) * 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
WO2019191032A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
WO2021189018A1 (en) 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
EP4121050A4 (en) * 2020-03-20 2024-04-17 Clear Creek Bio, Inc. STABLE POLYMORPHOUS COMPOSITIONS OF BREQUINA SODIUM, METHODS OF USE AND PRODUCTION THEREOF

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
ZA87279B (en) 1986-01-17 1987-09-30 Chugai Pharmaceutical Co Ltd Method for production of stable nicorandil preparation
KR940000232B1 (ko) 1986-01-17 1994-01-12 쥬우가이세이야꾸 가부시끼가이샤 니코란딜 제제의 안정화 방법
JP2512302B2 (ja) 1986-03-19 1996-07-03 中外製薬株式会社 ニコランジル安定化製剤の製造方法
KR910700043A (ko) 1988-12-28 1991-03-13 우에하라 아끼라 타정시에 있어서 응력분산 방법
JP2682353B2 (ja) 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
TW284688B (enExample) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
JP2006111639A (ja) 1993-10-21 2006-04-27 Takeda Chem Ind Ltd 医薬用錠剤
JPH08175996A (ja) 1994-12-22 1996-07-09 Taiyo Yakuhin Kogyo Kk ニコランジル安定化固形製剤の製法
JP3119801B2 (ja) 1995-09-28 2000-12-25 武田薬品工業株式会社 ビタミン含有組成物の安定化方法
JPH10245335A (ja) 1997-02-28 1998-09-14 Dainippon Pharmaceut Co Ltd 圧力に不安定な薬物の打錠方法及びそれに用いられる湿潤顆粒
EP1066040B1 (en) 1998-03-03 2003-02-19 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition containing cefuroxime axetil stable for moisture absorption
AT413647B (de) 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
DE10048510A1 (de) 2000-09-29 2002-05-16 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
WO2002067943A1 (en) 2001-02-27 2002-09-06 Ranbaxy Laboratories Limited Oral pharmaceutical composition of cefpodoxime proxetil
US7219132B2 (en) 2001-03-30 2007-05-15 Space Systems/Loral Dynamic resource allocation architecture for differentiated services over broadband communication networks
US7153851B2 (en) * 2002-03-18 2006-12-26 Kyorin Pharmaceutical Co., Ltd. 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium
DK1459739T3 (da) 2003-03-19 2008-05-19 Jordanian Pharmaceutical Mfg Ikke-hydroskopiske farmaceutiske sammensætninger indeholdende ikke-hydratiserede quinolin-carboxylsyrer
PT1666477E (pt) 2003-09-10 2013-08-28 Kyorin Seiyaku Kk Derivado de 7-(4-substituído-3-ciclopropilaminometil-1- pirrolidinil) quinolonecarboxílico
CN1980670A (zh) 2004-07-02 2007-06-13 第一制药株式会社 含有喹诺酮的医药组合物
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
JPWO2006059716A1 (ja) 2004-12-03 2008-06-05 武田薬品工業株式会社 固形製剤
AR052559A1 (es) 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
ATE518526T1 (de) 2005-01-26 2011-08-15 Lek Pharmaceuticals Neue pharmazeutische zusammensetzung mit candesartan-cilexetil als lipophile kristalline substanz
JP2006298811A (ja) 2005-04-20 2006-11-02 Taiyo Yakuhin Kogyo Kk ゲル化抑制製剤の設計
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
WO2013145749A1 (ja) 2012-03-29 2013-10-03 杏林製薬株式会社 カプセル製剤
WO2013145750A1 (ja) * 2012-03-29 2013-10-03 杏林製薬株式会社 カプセル製剤
WO2014174847A1 (ja) * 2013-04-25 2014-10-30 杏林製薬株式会社 固形医薬組成物

Also Published As

Publication number Publication date
CA2910112A1 (en) 2014-10-30
US9603804B2 (en) 2017-03-28
JPWO2014174846A1 (ja) 2017-02-23
WO2014174846A1 (ja) 2014-10-30
US20160067185A1 (en) 2016-03-10
CN105338982A (zh) 2016-02-17
JP5651812B1 (ja) 2015-01-14
EP2990038A1 (en) 2016-03-02
EP2990038B1 (en) 2019-11-20
EP2990038A4 (en) 2016-11-16
JP6391436B2 (ja) 2018-09-19
JP2015078201A (ja) 2015-04-23
CN105338982B (zh) 2017-10-10
ES2768651T3 (es) 2020-06-23

Similar Documents

Publication Publication Date Title
CA2910112C (en) Solid pharmaceutical composition
JP6689333B2 (ja) 固形医薬組成物
US20250099425A1 (en) Pharmaceutical compositions for treating cystic fibrosis
EP3697774B1 (en) Crystalline forms and compositions of cftr modulators
NO337235B1 (no) Nye sammensetninger inneholdende kinolinforbindelser
JP6349306B2 (ja) 錠剤
US20210206770A1 (en) Co-Crystal of an Orally Available Janus Kinase Inhibitor
TW201925190A (zh) 嘧啶基胺基─吡唑化合物之多晶型物及固體形式及製備方法
KR20250097874A (ko) 피리미딘 트리아졸 화합물의 고체 및 공결정형
WO2019008126A1 (en) NOVEL CRYSTALLINE FORM OF BCL-2 INHIBITOR, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
JP6018334B2 (ja) 固形医薬組成物
RU2822220C2 (ru) Фармацевтические композиции для лечения муковисцидоза
RU2822220C9 (ru) Фармацевтические композиции для лечения муковисцидоза
JP2020147528A (ja) ダビガトランエテキシラートを含む製剤および安定化方法
CA3048036A1 (en) Novel crystalline form of ribociclib succinate

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181227

MKLA Lapsed

Effective date: 20220425